Inpharma 1491 - 11 Jun 2005

EU orphan drug newsThe European Medicines Agency (EMEA) for the

Evaluation of Medical Products has granted orphan drugstatus to Viventia Biotech’s lead anti-cancer drug,VB 4845 [Proxinium], for the treatment of head and neckcancer.1

The EMEA’s Committee for Orphan MedicinalProducts has recommended orphan medicinal productdesignation of GPC Biotech AG’s monoclonal antibody1D09C3 for the treatment of Hodgkin’s lymphoma.2

1. Viventia Biotech Inc. Viventia’s Proxinium(TM) receives EU Orphan Drugdesignation. Media Release : 1 Jun 2005. Available from: URL: http://www.viventia.com.

2. GPC Biotech AG. European Regulatory Committee Recommends Orphan DrugStatus for GPC Biotech′s Anticancer Monoclonal Antibody 1D09C3 forHodgkin′s Lymphoma. Media Release : 2 Jun 2005. Available from: URL: http://www.gpc-biotech.com.

800999423

1

Inpharma 11 Jun 2005 No. 14911173-8324/10/1491-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved